Our news journalists obtained a quote from the research, "Dendritic cell-derived exosomes (Dex) have received much attention as immunotherapeutic anticancer agents since the discovery that they harbor functional MHC-peptide complexes, in addition to various other immune-stimulating components, that together facilitate immune cell-dependent tumor rejection. The therapeutic potential of Dex has been substantiated with their development and clinical testing in the treatment of cancer."
According to the news editors, the research concluded: "This review focuses on mechanisms by which Dex interact with and influence immune cells and describes how they can be engineered to promote their immunogenic capacity as novel and dynamic anticancer agents."
For more information on this research see: Dendritic Cell-Derived Exosomes as Immunotherapies in the Fight against Cancer.
The news correspondents report that additional information may be obtained from
Keywords for this news article include: Antigen-Presenting Cells,
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC
Most Popular Stories
- Consumer Prices Edge Up, Surprising Economists
- Steris to Add 100 Jobs in Birmingham
- Clinton Rallies New England Women
- Market Jolt Offers a Reality Check for Investors
- Stocks Close Out Best Week in Nearly 2 Years
- Do Voters Want Compromise?
- Timeline for New York Ebola Doctor
- Microsoft Earnings Drive Stocks Higher
- 'Kissing Congressman' Admits Mistake in Reelection Bid
- Ebola in New York, Mali Raises Travel Jitters